<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675244</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 08-1078-0010</org_study_id>
    <secondary_id>2U01HL088942-07</secondary_id>
    <nct_id>NCT02675244</nct_id>
  </id_info>
  <brief_title>Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery</brief_title>
  <official_title>Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Society for Thoracic and Cardiovascular Surgery</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research is to determine whether repairing a tricuspid valve (TV) in
      patients with mild to moderate tricuspid regurgitation (TR), at the time of planned mitral
      valve surgery (MVS), would improve the heart health of those who receive it compared to those
      who do not.

      At this point, the medical community is split in their opinion on whether surgeons should
      routinely repair mild to moderate TR in patients who are undergoing planned mitral valve
      surgery, and this study will answer this question.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The tricuspid valve controls the flow of blood in your heart between the right ventricle and
      the right atrium. TR is a condition where the valve does not close fully when it is supposed
      to and blood can then leak back into the right atrium. When TR becomes severe, surgery is
      usually performed to correct it. The purpose of the research is to determine whether
      repairing a tricuspid valve in patients with mild to moderate TR, at the time of planned
      mitral valve surgery, would improve the heart health of those who receive it compared to
      those who do not. There are no new or &quot;experimental&quot; procedures being tested in this study:
      both the mitral valve procedure and the tricuspid valve repair procedure are well established
      surgeries and are regularly performed together in patients who have severe TR. The available
      evidence addressing this issue is not definite: it is based on less rigorous methods of
      investigation, and the results have been conflicting. The study being proposed here will use
      rigorous scientific methods and should result in a very high level of certainty about what
      surgical treatment is best for patients with your condition.

      This study will enroll people scheduled for mitral valve surgery with mild to moderate
      tricuspid regurgitation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of TR Repair</measure>
    <time_frame>24 Months</time_frame>
    <description>Effectiveness of TR Repair assessed by a composite of death, reoperation for TR, or progression of TR from baseline by two grades or the presence of severe TR at 24 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACCE</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Major Adverse Cardiac and Cerebrovascular Events (MACCE) is defined as a non-weighted composite score comprised of the following components: Death, Stroke, and Serious heart failure events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Classification</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Functional status will be assessed by the New York Heart Association (NYHA) Classification scale which ranges from 1 (no physical limitations) to 4 (severe limitation of physical activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diuretic Use</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>The diuretic requirements of patients will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six Minute Walk Test</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>The total distance walked in six minutes will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of TR</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Degree of TR assessed by echocardiography, categorized according to American Society of Echocardiography guidelines as none/mild/moderate/severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Ventricular size</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Right ventricular (RV) size assessed by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of RV function</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Degree of RV function assessed by echocardiography as normal, mildly impaired, moderately impaired, severely impaired.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak tricuspid annular velocity</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Degree of RV function assessed by peak tricuspid annular velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tricuspid annular peak systolic excursion (TAPSE)</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Degree of RV function assessed by TAPSE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right ventricular fractional area change (RVFAC)</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Degree of RV function assessed by RVFAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Artery Pressure</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Pulmonary artery pressure assessed by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Ventricular Volume</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>RV Volume as measured by transthoracic 3D echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Quality of Life assessed by SF-12. A measure of perceived health (health-related quality of life [QoL]) that describes the degree of general physical health status and mental health distress. Higher scores indicate higher levels of health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Quality of Life assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ). KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQoL (EQ-5D)</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Quality of Life assessed by EuroQoL (EQ-5D) - a standardised instrument for use as a measure of health outcome. Higher scores indicate higher levels of health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>up to 60 Months</time_frame>
    <description>Incidence of participants alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Index Hospitalization</measure>
    <time_frame>average 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Incidence of readmissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperations</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Incidence of reoperations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic Measures (Inpatient costs)</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Inpatient costs will be measured through the collection of hospital billing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>60 months</time_frame>
    <description>Safety as measured by frequency of serious adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AV-Block requiring pacemaker implantation</measure>
    <time_frame>60 months</time_frame>
    <description>Safety as measured by frequency of AV-Block requiring pacemaker implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New-onset atrial fibrillation</measure>
    <time_frame>60 months</time_frame>
    <description>Safety as measured by frequency new-onset atrial fibrillation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Mild Tricuspid Regurgitation</condition>
  <condition>Moderate Tricuspid Regurgitation</condition>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>MVS Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will undergo mitral valve surgery alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MVS + TV Annuloplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo mitral valve surgery and tricuspid valve annuloplasty.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TV Annuloplasty</intervention_name>
    <description>TV Annuloplasty will be performed using standard surgical techniques</description>
    <arm_group_label>MVS + TV Annuloplasty</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MVS</intervention_name>
    <description>MVS will be performed using standard surgical techniques</description>
    <arm_group_label>MVS Alone</arm_group_label>
    <arm_group_label>MVS + TV Annuloplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing MVS for degenerative MR with (a) Moderate TR as determined by transthoracic
             2D echocardiography, or (b) Tricuspid annular dimension ≥ 40 mm (index: ≥21mm/M2 BSA)
             and trace/mild TR, determined by echocardiography.

          -  Age ≥ 18 years

          -  Able to sign Informed Consent and Release of Medical Information forms

        Exclusion Criteria:

          -  Functional MR

          -  Evidence of sub-optimal fluid management (e.g., lack of diuretics, weight in excess of
             dry weight) in the opinion of the cardiology investigator

          -  Structural / organic TV disease

          -  Severe TV regurgitation as determined by preoperative transthoracic echocardiography
             (TTE)

          -  Implanted pacemaker or defibrillator, where the leads cross the TV from the right
             atrium into the right ventricle

          -  Concomitant cardiac surgery other than atrial fibrillation correction surgery (PVI,
             Maze, LAA closure), closure of PFO or ASD, or CABG

          -  Cardiogenic shock at the time of randomization

          -  STEMI requiring intervention within 7 days prior to randomization

          -  Evidence of cirrhosis or hepatic synthetic failure

          -  Severe, irreversible pulmonary hypertension in the judgment of the investigator

          -  Pregnancy at the time of randomization

          -  Therapy with an investigational intervention at the time of screening, or plan to
             enroll patient in additional investigational intervention study during participation
             in this trial

          -  Any concurrent disease with life expectancy &lt; 2 years

          -  Unable or unwilling to provide informed consent

          -  Unable or unwilling to comply with study follow up in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annetine C. Gelijns, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Weisel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Toronto General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen Moquete, RN</last_name>
    <phone>212-659-9651</phone>
    <email>ellen.moquete@mountsinai.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Lozano</last_name>
      <phone>323-409-5573</phone>
      <email>edwardlo@med.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sylvia Ramos</last_name>
      <phone>323-442-5763</phone>
      <email>sylvia.ramos@usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Bowdish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kokil Bakshi</last_name>
      <phone>650-498-1232</phone>
      <email>kbakshi@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Y. Joseph Woo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine - Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnar Geirsson, MD</last_name>
      <phone>203-785-5252</phone>
    </contact>
    <investigator>
      <last_name>Arnar Geirsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Prince</last_name>
      <email>t.prince@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kim Baio</last_name>
      <phone>404-686-3374</phone>
      <email>kim.baio@emoryhealthcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Vinod Thourani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Deasey</last_name>
      <phone>410-328-2737</phone>
      <email>sdeasey@smail.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>James S Gammie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suburban Hospital</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandy Murphy, RN</last_name>
      <phone>301-896-3775</phone>
      <email>mmurph70@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ann Greenberg</last_name>
      <phone>301-896-2473</phone>
      <email>agreen64@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Philip Corcoran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health Services</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathie Bloem, MPH, RN</last_name>
      <phone>734-615-6170</phone>
      <email>bloem@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Bolling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cori Larson, CCRP</last_name>
      <phone>507-255-0036</phone>
      <email>larson.cori@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Simon Maltais, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry C Stokes, RN</last_name>
      <phone>603-650-6134</phone>
      <email>henry.c.stokes@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Jock McCullough, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyn Goldsmith, RN, CCRC</last_name>
      <phone>212-342-0261</phone>
      <email>lg2240@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Argenziano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Einstein Heart Center</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Garcia, RN</last_name>
      <phone>718-920-6742</phone>
      <email>jugarcia@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Robert E. Michler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Mangusan</last_name>
      <phone>828-213-5673</phone>
      <email>Ralph.Mangusan@msj.org</email>
    </contact>
    <contact_backup>
      <last_name>Lynne C Hampton</last_name>
      <phone>828-213-7032</phone>
      <email>lynne.hampton@msj.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mark A Groh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greg Tipton</last_name>
      <phone>919-684-4491</phone>
      <email>greg.tipton@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Strippy</last_name>
      <phone>216-444-0379</phone>
      <email>STRIPPB@ccf.org</email>
    </contact>
    <investigator>
      <last_name>A. Marc Gillinov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Fadorsen, RN</last_name>
      <phone>614-292-5315</phone>
      <email>Denise.Fadorsen@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Bryan Whitson, Whitson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Lou Mayer, RN</last_name>
      <phone>215-662-7981</phone>
      <email>marylou.mayer@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christine Gepty</last_name>
      <phone>215-615-0570</phone>
      <email>christine.gepty@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Acker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Worley</last_name>
      <phone>972-566-4083</phone>
      <email>tworley@crsti.org</email>
    </contact>
    <investigator>
      <last_name>Michael Mack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health Systems</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra G Burks, RN, CCRC</last_name>
      <phone>434-243-0315</phone>
      <email>sgb2c@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Irving L Kron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaelin M Grant, CCRC</last_name>
      <phone>608-262-1551</phone>
      <email>grantk@surgery.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Nilto De Oliveira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asvina Bissonath, BSc, MRes.</last_name>
      <phone>780-407-6327</phone>
      <email>asvina.bissonauth@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>John C Mullen, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Fox, BA, RRT</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>ext. 35031</phone_ext>
      <email>Stephanie.Fox@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Michael Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nishit Fumakia</last_name>
      <phone>416-340-3491</phone>
      <email>nishit.fumakia@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Terry Yau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Robichaud</last_name>
      <phone>514-376-3330</phone>
      <phone_ext>3305</phone_ext>
      <email>Sophie.Robichaud@icm-mhi.org</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan Lacharité</last_name>
      <phone>514-376-3330</phone>
      <email>jonathan.lacharite@icm-mhi.org</email>
    </contact_backup>
    <investigator>
      <last_name>Louis Perrault, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geneviève Peloquin</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>14362</phone_ext>
      <email>genevieve.peloquin.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Nicolas Noiseux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Sacré-Cœur de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole Sirois</last_name>
      <phone>514-338-2222</phone>
      <phone_ext>3083</phone_ext>
      <email>carole.sirois@crhsc.rtss.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Huges Jeanmart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie de Quebec (Hopital Laval)</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Landry</last_name>
      <phone>418-656-8711 ext 5751</phone>
      <email>Patricia.Landry@criucpq.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Tremblay Hugo</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>3797</phone_ext>
      <email>hugo.tremblay@criucpq.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre Voisine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inga Scheida</last_name>
      <email>ischeida@dhzb.de</email>
    </contact>
    <investigator>
      <last_name>Volkmar Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Center, University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Lechner</last_name>
      <email>gabriele.lechner@universitaets-herzzentrum.de</email>
    </contact>
    <investigator>
      <last_name>Friedhelm Beyersdorf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tricuspid Valve Regurgitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

